TRILUMINATE trial shows “extremely favourable” results in patients with tricuspid regurgitation

Speaking to Cardiovascular News at EuroPCR 2019, Georg Nickenig (Bonn, Germany), discusses the results of the TRILUMINATE trial which looked at the safety and efficacy of treating tricuspid regurgitation with a novel tricuspid valve repair system.

The trial results showed no death, cardiovascular mortality, stroke, or myocardial infarction at 30 days and this despite a “very sick patient population”. As a results, safety was “extremely favourable” and efficacy was “also very promising” with tricuspid regurgitation reduced in 90% of the patients.

Nickenig also outlines why percutaneous trancatheter intervention is his preferred approach to dealing with patients who have tricuspid regurgitation and explains in which patients such a procedure would not be appropriate.

EuroPCR 2019,TRILUMINATE,trial,tricuspid regurgitation,safety,efficacy,valve repair,percutaneous trancatheter intervention,mortality,stroke,myocardial infarction,